| Press releases

Formycon Releases Updates on Development Programs and Milestones

FYB201 provides positive 48-week data after completion of Phase III study. In addition to the achievement of the primary efficacy endpoint the study showed comparable results with regard to efficacy, safety and immunogenicity between the investigational medicinal product FYB201 and the reference medicinal product Lucentis® (ranibizumab).

Calendar

Munich Capital Market Conference

December 11–12, 2018

Financial reports
gb17-teaser-de

Annual Report 2017

Published on:
May 7, 2018

  • Forschung_und_Entwicklung_2018_web_en
  • Teaser_mitglied-bio-deutschland-en
  • Teaser_mitglied-biosimilar-medicines-en
  • teaser-powerlist
  • teaser-wachstumschampion-en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out, one project has been transferred into a joint venture.